Watch COLL. Know when insiders buy.
One email the day a filing lands. Free.
COLL
COLLEGIUM PHARMACEUTICAL, INC
22.92
−0.44 −1.88%
USD · close Sep 10
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $746.2MP/E 18.5DIV YIELD —FCF YIELD 43.99%REV TTM $808.2M +14.3%NET INCOME $47.9M +32.1%NET CASH $118M52W 22.92 – 49.84SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $199.9M | +6.3% | 55.2% | $3.7M | −$15.1M | −225.6% | -0.46 | $71.3M | $496K | $70.8M | Aug 6 |
| Q1 2026 · Mar 31 | $193.5M | +8.9% | 60.6% | $30.9M | $14.5M | +499.8% | 0.40 | $57.1M | $270K | $56.8M | Aug 6 |
| Q4 2025 · Dec 31 | $205.4M | +12.9% | 62.5% | $60.8M | $17M | +35.3% | 0.46 | $123M | $689K | $122.4M | Feb 26 |
| Q3 2025 · Sep 30 | $209.4M | +31.4% | 61.7% | $62.1M | $31.5M | +237.5% | 0.84 | $78.4M | $188K | $78.3M | Feb 26 |
| Q2 2025 · Jun 30 | $188M | +29.4% | 57.7% | $35.1M | $12M | −38.9% | 0.34 | $72.4M | $65K | $72.4M | Aug 6 |
| Q1 2025 · Mar 31 | $177.8M | +22.7% | 54.8% | $21.7M | $2.4M | −91.3% | 0.07 | $55.4M | $798K | $54.6M | Aug 6 |
| Q4 2024 · Dec 31 | $181.9M | +21.5% | 54.0% | $38.1M | $12.5M | −60.8% | 0.36 | $84.6M | $570K | $84.1M | Feb 26 |
| Q3 2024 · Sep 30 | $159.3M | +16.5% | 60.8% | $34.8M | $9.3M | −54.8% | 0.27 | −$9M | $244K | −$9.2M | Feb 26 |
| Q2 2024 · Jun 30 | $145.3M | — | 62.5% | $47.5M | $19.6M | — | 0.52 | $67.4M | $270K | $67.1M | Feb 26 |
| Q1 2024 · Mar 31 | $144.9M | — | 63.1% | $49.5M | $27.7M | — | 0.71 | $61.9M | $568K | $61.4M | Feb 26 |
| Q4 2023 · Dec 31 | $149.7M | — | 63.2% | $61.7M | $31.9M | — | 0.82 | $73.3M | $164K | $73.2M | Feb 26 |
| Q3 2023 · Sep 30 | $136.7M | — | 58.7% | $45M | $20.6M | — | 0.53 | $74M | $65K | $74M | Feb 27 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $780.6M | 59.3% | $179.6M | $62.9M | 8.1% | 1.73 | $329.3M | $1.7M | $327.6M | $25.1M | — |
| FY2024 · to Dec 31 | $631.4M | 59.8% | $169.9M | $69.2M | 11.0% | 1.86 | $205M | $1.7M | $203.3M | $60M | — |
| FY2023 · to Dec 31 | $566.8M | 57.5% | $167M | $48.2M | 8.5% | 1.29 | $274.7M | $461K | $274.3M | $75M | — |
| FY2022 · to Dec 31 | $463.9M | 45.2% | $33.3M | −$25M | -5.4% | -0.74 | $124.2M | $1.6M | $122.6M | $14.1M | — |
| FY2021 · to Dec 31 | $276.9M | 54.4% | $17.6M | $71.5M | 25.8% | 1.86 | $103.6M | $1.9M | $101.6M | $47.9M | — |
| FY2020 · to Dec 31 | $310M | 58.0% | $56.2M | $26.8M | 8.6% | 0.76 | $93.9M | $5.5M | $88.4M | — | — |
Every number comes from COLLEGIUM PHARMACEUTICAL, INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.